Zobrazeno 1 - 10 of 154 pro vyhledávání: '"Yoav H Messinger"'
1
Akademický článek
Impact of the COVID-19 pandemic on utilization and cost for care of pediatric and young adult ALL
Autor: Alex Hoover, Dave Watson, Paige Reimche, Lynn Tanner, Laura Gilchrist, Mike Finch, Yoav H Messinger, Lucie M. Turcotte
Publikováno v: BMC Research Notes, Vol 17, Iss 1, Pp 1-4 (2024)
Abstract Objective Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and among the most common malignancies in young adults and requires a unique pattern of healthcare utilization including an acute/emergent presentation and
Externí odkaz: https://doaj.org/article/96c9a53faabe47528ac86a6ace030474
Zobrazit plný text záznamu
2
Akademický článek
Liver fibrosis among infants with t(1;22)(p13;q13) acute megakaryoblastic leukemia: a case report and literature review
Autor: Nira Arad-Cohen, Ori Attias, Yaniv Zohar, Yoav H. Messinger
Publikováno v: Frontiers in Oncology, Vol 14 (2024)
This case report describes a 2-month-old girl with acute megakaryoblastic leukemia (AMKL) harboring the t(1;22)(p13;q13) translocation, resulting in the RBM15::MRTFA fusion gene. She presented with massive hepatosplenomegaly and liver fibrosis and ac
Externí odkaz: https://doaj.org/article/6717e1a833324ca987a961e9098df4d3
Zobrazit plný text záznamu
3
Akademický článek
Healthcare cost and utilization for chimeric antigen receptor (CAR) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis
Autor: Alex Hoover, Paige Reimche, Dave Watson, Lynn Tanner, Laura Gilchrist, Mike Finch, Yoav H. Messinger, Lucie M. Turcotte
Publikováno v: Cancer Reports, Vol 7, Iss 2, Pp n/a-n/a (2024)
Abstract Background B‐lineage acute lymphoblastic leukemia (B‐ALL) is the most common malignancy of childhood. With the introduction of novel cellular therapies, cost of care is a critical component and the financial burden experienced by patient
Externí odkaz: https://doaj.org/article/437debd053674aa1a5721fdd11d75d09
Zobrazit plný text záznamu
4
Real-World Cost of Pediatric Acute Lymphoblastic Leukemia Care Among Commercially Insured Individuals in the United States: Effect of Era and Age at Diagnosis
Autor: Lucie M. Turcotte, Dave Watson, Lynn Tanner, Alex Hoover, Laura Gilchrist, Mike Finch, Yoav H. Messinger
Publikováno v: JCO oncology practice. 18(11)
PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Five-year survival is approaching 90%. In efforts to further improve outcomes, it is critical to consider the cost of ALL care. MATERIALS AND METHODS: Commercial ins
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70f6cb99e49235181d8fa19a8ae53d95
https://pubmed.ncbi.nlm.nih.gov/36166724
Zobrazit plný text záznamu
5
Akademický článek
STXBP2-R190C Variant in a Patient With Neonatal Hemophagocytic Lymphohistiocytosis (HLH) and G6PD Deficiency Reveals a Critical Role of STXBP2 Domain 2 on Granule Exocytosis
Autor: Nathalia Benavides, Waldo A. Spessott, Maria L. Sanmillan, Marcelo Vargas, Mylynda S. Livingston, Nissa Erickson, Tamara C. Pozos, Margaret E. McCormick, Emilia Scharrig, Yoav H. Messinger, Claudio G. Giraudo
Publikováno v: Frontiers in Immunology, Vol 11 (2020)
Neonatal hemophagocytic lymphohistiocytosis (HLH) is a medical emergency that can be associated with significant morbidity and mortality. Often these patients present with familial HLH (f-HLH), which is caused by gene mutations interfering with the c
Externí odkaz: https://doaj.org/article/18dbbd268bc545599c209ae63407fe44
Zobrazit plný text záznamu
10
Akademický článek
Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II
Autor: Katherine H. Kim, Yoav H. Messinger, Barbara K. Burton
Publikováno v: Molecular Genetics and Metabolism Reports, Vol 2, Iss C, Pp 20-24 (2015)
We report on a 6 year old boy with severe MPS II undergoing immune modulation therapy due to high IgG antibody titers to IV idursulfase and no significant decline in urinary GAG levels since initiating enzyme replacement therapy. He has complete defi
Externí odkaz: https://doaj.org/article/7170e94c63cf4da2a9b0d8e64681e870
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje